Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by University of Alabama at Birmingham
Sponsor:
Collaborators:
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
University Health Network, Toronto
University of Michigan
Dana-Farber Cancer Institute
Mayo Clinic
University of Washington
City of Hope National Medical Center
M.D. Anderson Cancer Center
University of Chicago
University of Minnesota - Clinical and Translational Science Institute
University of Colorado, Denver
Wake Forest University
Information provided by (Responsible Party):
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01196936
First received: September 3, 2010
Last updated: May 14, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2019
  Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)